Juan Francisco Sánchez Muñoz-Torrero-rekin lankidetzan egindako argitalpenak (9)

2022

  1. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

    Research and Practice in Thrombosis and Haemostasis, Vol. 6, Núm. 4

  2. Predictors of use of direct oral anticoagulants in patients with venous thromboembolism: Findings from the Registro Informatizado Enfermedad Tromboembólica registry

    Frontiers in Medicine, Vol. 9

2020

  1. D-dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry

    Journal of Internal Medicine, Vol. 287, Núm. 1, pp. 32-41

  2. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: The BACS score

    European Respiratory Journal, Vol. 56, Núm. 6

  3. First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry

    Thrombosis Update, Vol. 1

2018

  1. Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry

    Journal of Thrombosis and Thrombolysis, Vol. 46, Núm. 4, pp. 551-558

2015

  1. Fatal events in cancer patients receiving anticoagulant therapy for venous thromboembolism

    Medicine (United States), Vol. 94, Núm. 32

  2. Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices?

    PLoS ONE, Vol. 10, Núm. 6

2014

  1. Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy

    European Journal of Internal Medicine, Vol. 25, Núm. 9, pp. 821-825